Pharmaceutical intermediates
Linzagolix Choline Intermediates
7 pharmaceutical intermediates for Linzagolix Choline. Indication: Leiomyoma.
About Linzagolix Choline
- Originator
- Kissei Pharmaceutical Co., Ltd.
- Indication
- Leiomyoma
Available intermediates
7 intermediates currently listed for Linzagolix Choline. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 4-Fluoro-2-methoxyphenol | 450-93-1 | / | / |
| 2,3-Difluoro-6-methoxybenzaldehyde | 187543-87-9 | / | / |
| 5-((2,3-difluoro-6-methoxybenzyloxy)-2-fluoro-4-methoxyaniline | 935287-59-5 | / | / |
| Dimethyl 4-(phenoxycarbonylamino)thiophene-2,3-dicarboxylate | 1581731-15-8 | / | / |
| 1,2-difluoro-3-((4-fluoro-2-methoxy-5-nitrophenoxy)methyl)-4-methoxybenzene | 1073435-71-8 | / | / |
| 2,3-Difluoro-6-methoxybenzyl Chloride | 1073435-67-2 | / | / |
| Dimethyl 4-aminothiophene-2,3-dicarboxylate hydrochloride | 121071-71-4 | / | / |
Building toward Linzagolix Choline?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →